ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients
- Authors: 5th European Conference on Infections in Leukaemia (ECIL-5), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), Alanio A, Bretagne S, Cesaro S, Cordonnier C, Donnelly JP, Einsele H, Hauser PM, Helweg-Larsen J, Lagrou K, Maertens J, Maschmeyer G, Matos O, Melchers WJ, the European LeukemiaNet (ELN), The European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS)
- Publication Year: 2016
- Journal: Journal of Antimicrobial Chemotherapy
- Link: https://academic.oup.com/jac/article/71/9/2397/2237828
The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice […]
Read More

